---
figid: PMC9071022__jinfn-45-142-g007
pmcid: PMC9071022
image_filename: jinfn-45-142-g007.jpg
figure_link: /pmc/articles/PMC9071022/figure/F7/
number: Figure 7
figure_title: ''
caption: 'Patient treatment pathway with avelumab 1L maintenance in UC: role of infusion
  nurses. Abbreviations: 1L, first-line; irAE, immune-related adverse event; UC, urothelial
  carcinoma.'
article_title: 'Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer:
  Practical Implementation Steps for Infusion Nurses.'
citation: Laura S. Wood, et al. J Infus Nurs. 2022 May;45(3):142-153.
year: '2022'

doi: 10.1097/NAN.0000000000000465
journal_title: Journal of Infusion Nursing
journal_nlm_ta: J Infus Nurs
publisher_name: Wolters Kluwer Health, Inc.

keywords:
- adverse event management
- avelumab
- bladder cancer
- immune checkpoint inhibitor
- infusion nurse
- infusion reactions
- maintenance therapy
- oncology
- toxicity management
- urothelial cancer

---
